FDA has approved the first oral PCSK9 inhibitor to reduce LDL ("bad") cholesterol in adults with high cholesterol. Until now, PCSK9 inhibitors were only availab

FDA has approved the first oral PCSK9 inhibitor to reduce LDL ("bad") cholesterol in adults with high cholesterol. Until now, PCSK9 inhibitors were only available as injections. The once-daily tablet provides an additional treatment option for adults who need further LDL-C reduction despite existing…